AVA 001

Drug Profile

AVA 001

Alternative Names: AVA-101; AVA-201; rAAV.sFlt-1

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avalanche Biotechnologies
  • Developer Adverum Biotechnologies
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic macular oedema; Retinal vein occlusion
  • Research Wet age-related macular degeneration

Most Recent Events

  • 01 Aug 2017 Avalanche Biotechnologies completes a phase I/II trial for Wet age-related macular degeneration (In the elderly) in Australia (Intraocular) (NCT01494805)
  • 02 Sep 2015 Preclinical trials in Diabetic macular oedema and Retinal vein occlusion in USA (Intraocular) before September 2015 (Avalanche Biotechnologies Pipeline, September 2015)
  • 24 Aug 2015 Avalanche Biotechnologies has patents pending for AVA 101/AVA 201 in several countries worldwide (Avalanche 10-K, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top